Literature DB >> 15272498

Cetuximab.

Joanne Graham, Mohamed Muhsin, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15272498     DOI: 10.1038/nrd1445

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  53 in total

1.  Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors.

Authors:  Robert Y C Yang; Katherine S Yang; Linda J Pike; Garland R Marshall
Journal:  Chem Biol Drug Des       Date:  2010-05-04       Impact factor: 2.817

2.  Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.

Authors:  Mari Iida; Toni M Brand; Megan M Starr; Chunrong Li; Evan J Huppert; Neha Luthar; Mikkel W Pedersen; Ivan D Horak; Michael Kragh; Deric L Wheeler
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

Review 3.  Biological agents in gastrointestinal cancers: adverse effects and their management.

Authors:  Nivedita Arora; Arjun Gupta; Preet Paul Singh
Journal:  J Gastrointest Oncol       Date:  2017-06

4.  Epidermal growth factor receptor-targeted poly(amidoamine)-based dendrimer complexed oncolytic adenovirus: is it safe totally?

Authors:  Min Huang; Chun-Sheng Yang; Yong Xin; Guan Jiang
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

Review 5.  Omics and therapy - a basis for precision medicine.

Authors:  Joseph P Garay; Joe W Gray
Journal:  Mol Oncol       Date:  2012-03-08       Impact factor: 6.603

6.  Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.

Authors:  Jennifer L Macdonald-Obermann; Sangeeta Adak; Ralf Landgraf; David Piwnica-Worms; Linda J Pike
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

7.  Computationally driven antibody engineering enables simultaneous humanization and thermostabilization.

Authors:  Yoonjoo Choi; Christian Ndong; Karl E Griswold; Chris Bailey-Kellogg
Journal:  Protein Eng Des Sel       Date:  2016-06-21       Impact factor: 1.650

8.  AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis.

Authors:  Xiaoan Tao; Yang Lu; Songbo Qiu; Yi Wang; Jun Qin; Zhen Fan
Journal:  Cancer Lett       Date:  2017-08-18       Impact factor: 8.679

9.  ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.

Authors:  Haiquan Lu; Xinqun Li; Yang Lu; Songbo Qiu; Zhen Fan
Journal:  Cancer Lett       Date:  2016-07-19       Impact factor: 8.679

Review 10.  Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design.

Authors:  Sitanshu S Singh; Seetharama D Jois
Journal:  Adv Protein Chem Struct Biol       Date:  2017-10-06       Impact factor: 3.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.